Evolution in the Management of Oligometastatic Prostate Cancer: What Does the Evidence Show When Selecting the Treatment of Choice?
Type
Webinaire
DÉTAILS DE L’ACTIVITÉ
Display Date
Monday, April 7, 2025
Display Date Line 2
19:00 ET
Location
Virtual
Speaker
Alejandro Berlin, Frédéric Pouliot & Ricardo Rendon
CRÉDITS
Accreditation
Section 1 Group Learning Credits
Event Description
Speakers: Alejandro Berlin, Frédéric Pouliot & Ricardo Rendon
Objectives
By participating in this learning program, healthcare providers can expect to:
- Understand the treatment options for de novo, castrate-sensitive, and castrate-resistant oligometastatic prostate cancer.
- Differentiate between length of therapy and duration of testosterone suppression for optimal patient outcomes.
- Discuss the application of evidence-based medicine in determining the place of various treatment options through patient cases.
Footer
ACCREDITATION
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.
_______________________________________________________________________
